GlassScriptPhysician profile
Susan Scott
NPI 1164816138
$42,052.26
in general payments reported to CMS, 2019-2025
15 companies · $12K in 2025
The $12K reported for 2025 was more than what 82% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $4,514 · 2023: $7,189 · 2024: $19K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Food and Beverage: $2,137 · Travel and Lodging: $1,098 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,286.50 |
| Food and Beverage | $2,136.89 |
| Travel and Lodging | $1,098.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,631.44 | 2023-2025 | Tagrisso, Imfinzi |
| Genentech USA, INC. | $7,604.65 | 2022-2025 | Tecentriq, Rozlytrek, Alecensa |
| Regeneron Pharmaceuticals, INC. | $6,370.72 | 2023-2024 | Libtayo |
| Daiichi Sankyo INC. | $3,439.82 | 2024-2025 | Enhertu, Datroway |
| Astrazeneca Uk Limited | $3,318.16 | 2025 | Tagrisso |
| Janssen Global Services, LLC | $3,022.05 | 2024-2025 | Rybrevant |
| Janssen Biotech, INC. | $2,635.21 | 2024-2025 | Rybrevant |
| Emd Serono, INC. | $2,115.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $1,751.02 | 2023-2025 | Libtayo |
| Janssen Scientific Affairs, LLC | $1,665.00 | 2025 | Rybrevant |
| Mirati Therapeutics, INC. | $163.72 | 2023 | Krazati |
| Novocure INC. | $158.35 | 2024 | Optune Lua (Novottf-200t) |
| Seagen INC. | $109.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $50.77 | 2022 | |
| Janssen Research & Development, LLC | $16.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.